Transgenic Animal Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By PCR, By Technique, By Application, By Model Organisms, By End User, By Region & Competition, 2021-2031F

Description

The Global Transgenic Animal Market is projected to expand from USD 4.18 Billion in 2025 to USD 7.63 Billion by 2031, reflecting a compound annual growth rate of 10.55%. This industry involves the commercialization and use of organisms with deliberately altered genetic material to express specific, desirable traits for research or bioproduction. Key factors propelling this expansion include the growing need for predictive animal models to investigate chronic human ailments and the increasing demand for recombinant proteins and monoclonal antibodies within the biopharmaceutical field. Additionally, continuous improvements in gene-editing technologies act as a critical growth engine, allowing for the precise creation of animals that replicate complex physiological states essential for robust drug discovery and development.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 4.18 Billion
Market Size 2031	USD 7.63 Billion
CAGR 2026-2031	10.55%
Fastest Growing Segment	Gene Gun
Largest Market	North America

Despite these positive drivers, the market faces substantial hurdles due to strict ethical regulations and rising public concern over animal welfare, which can delay regulatory approvals and heighten compliance expenses. Nonetheless, the scientific community continues to rely heavily on these models for essential research. Data from Understanding Animal Research in 2024 indicated that 45% of all regulated scientific procedures in Great Britain were specifically dedicated to creating or breeding genetically altered animals, highlighting the enduring and critical volume of this segment in biomedical innovation.

Market Driver

Breakthroughs in Genome Editing and Engineering Technologies serve as the primary catalyst for the Global Transgenic Animal Market. The integration of high-precision tools, such as CRISPR-Cas9, has revolutionized the capability to engineer animals with specific genetic modifications, enabling the development of organisms with human-compatible organs or precise disease phenotypes. This technological maturation has drawn significant investment, particularly for xenotransplantation applications where genetically modified pigs act as viable organ donors. For instance, eGenesis announced in September 2024 that it secured $191 million in Series D financing to advance its genetically engineered porcine kidney candidate into first-in-human clinical trials, demonstrating strong commercial confidence in these genomic platforms.

Concurrently, the market is significantly bolstered by the escalating demand for predictive preclinical human disease models. With the rise of complex chronic conditions, pharmaceutical developers require sophisticated in vivo systems to screen potential therapies and prevent late-stage clinical failures. In January 2024, the American Cancer Society's "Cancer Facts & Figures 2024" report projected that new cancer cases in the United States would surpass 2 million for the first time, emphasizing the urgent need for advanced oncology models. This disease burden drives massive capital allocation toward discovery pipelines utilizing transgenic organisms; illustrating this scale, Merck & Co. reported a total research and development expenditure of $30.5 billion for the full year 2023 in February 2024, reflecting the immense financial support for biomedical innovation.

Market Challenge

A major obstacle to the Global Transgenic Animal Market's growth is the presence of rigorous ethical regulations and increasing public scrutiny concerning animal welfare. Regulatory bodies worldwide are implementing stricter standards, compelling organizations to undergo exhaustive ethical reviews and strictly adhere to the principles of Replacement, Reduction, and Refinement. These compliance requirements demand significant investment in oversight and documentation, which extends development timelines and raises operational costs, ultimately discouraging the expansion of animal-based research and incentivizing the adoption of non-animal alternative methodologies.

The tangible impact of these restrictions is evident in recent operational data showing a contraction in the utilization of transgenic models. According to Understanding Animal Research, the number of procedures involving the creation and breeding of genetically altered animals in Great Britain decreased by 0.5% in 2024 compared to the previous year. This decline underscores the correlation between intensifying regulatory pressures and the dampening of market activities, as research institutions and pharmaceutical companies are forced to limit their reliance on these complex biological models due to the mounting ethical and administrative burdens.

Market Trends

A fundamental shift reshaping the transgenic animal market is the strategic outsourcing of model generation to Contract Research Organizations. Pharmaceutical firms are increasingly divesting from capital-intensive in-house breeding programs to mitigate the high fixed costs associated with facility maintenance and regulatory compliance. This transition allows drug developers to convert fixed overheads into variable costs while accessing specialized colonies that require complex husbandry. The financial impact of this operational shift is visible in the recent performance of key service providers; Charles River Laboratories reported in November 2024 that revenue for its Research Models and Services segment rose by 5.9% to $197.8 million in its third-quarter results, indicating a growing industry reliance on external partners.

Simultaneously, the market is witnessing a surge in the development of humanized immuno-oncology models specifically designed to evaluate complex immunotherapies. Unlike traditional transgenic organisms, these specialized platforms are engineered to host functional human immune systems, enabling researchers to test the efficacy of checkpoint inhibitors and antibody-drug conjugates in a systemic environment. This trend is distinct from general disease modeling as it focuses on the precise reconstitution of human immunological responses within the animal host to reduce translational failure rates. The commercial expansion of this niche is substantiated by companies like Champions Oncology, which reported a 17% revenue increase to $13.5 million in its fiscal 2025 second-quarter results in December 2024, reflecting the intensifying uptake of these specialized oncology solutions.

Key Market Players

C.H. Boehringer Sohn Ko. KG
ELIAS Animal Health, LLC
Zoetis Inc.
AB Science S.A.
Karyopharm Therapeutics, Inc.
Vivesto AB
Merial Inc.
Elanco Animal Health, Inc.
Dechra Pharmaceuticals PLC
Torigen Pharmaceuticals Inc

Report Scope

In this report, the Global Transgenic Animal Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transgenic Animal Market, By Product

Gene Gun
PCR
Microinjections
Others

Transgenic Animal Market, By PCR

Real-Time PCR
Digital PCR Systems
Others

Transgenic Animal Market, By Technique

DNA Microinjection
Embryonic Stem Cell-Mediated Gene Transfer
Retrovirus-Mediated Gene Transfer
Others

Transgenic Animal Market, By Application

Recombinant Human Proteins
Monoclonal Antibodies
Xenotransplantation
Others

Transgenic Animal Market, By Model Organisms

Mice
Rabbit
Cow
Others

Transgenic Animal Market, By End User

Biotechnology & Pharmaceutical Companies
Academic & Research Organizations
Others

Transgenic Animal Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transgenic Animal Market.

Available Customizations:

Global Transgenic Animal Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transgenic Animal Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Gene Gun, PCR, Microinjections, Others)
- 5.2.2. By PCR (Real-Time PCR, Digital PCR Systems, Others)
- 5.2.3. By Technique (DNA Microinjection, Embryonic Stem Cell-Mediated Gene Transfer, Retrovirus-Mediated Gene Transfer, Others)
- 5.2.4. By Application (Recombinant Human Proteins, Monoclonal Antibodies, Xenotransplantation, Others)
- 5.2.5. By Model Organisms (Mice, Rabbit, Cow, Others)
- 5.2.6. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Organizations, Others)
- 5.2.7. By Region
- 5.2.8. By Company (2025)
5.3. Market Map

6. North America Transgenic Animal Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By PCR
- 6.2.3. By Technique
- 6.2.4. By Application
- 6.2.5. By Model Organisms
- 6.2.6. By End User
- 6.2.7. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Transgenic Animal Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By PCR
    - 6.3.1.2.3. By Technique
    - 6.3.1.2.4. By Application
    - 6.3.1.2.5. By Model Organisms
    - 6.3.1.2.6. By End User
- 6.3.2. Canada Transgenic Animal Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By PCR
    - 6.3.2.2.3. By Technique
    - 6.3.2.2.4. By Application
    - 6.3.2.2.5. By Model Organisms
    - 6.3.2.2.6. By End User
- 6.3.3. Mexico Transgenic Animal Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By PCR
    - 6.3.3.2.3. By Technique
    - 6.3.3.2.4. By Application
    - 6.3.3.2.5. By Model Organisms
    - 6.3.3.2.6. By End User

7. Europe Transgenic Animal Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By PCR
- 7.2.3. By Technique
- 7.2.4. By Application
- 7.2.5. By Model Organisms
- 7.2.6. By End User
- 7.2.7. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Transgenic Animal Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By PCR
    - 7.3.1.2.3. By Technique
    - 7.3.1.2.4. By Application
    - 7.3.1.2.5. By Model Organisms
    - 7.3.1.2.6. By End User
- 7.3.2. France Transgenic Animal Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By PCR
    - 7.3.2.2.3. By Technique
    - 7.3.2.2.4. By Application
    - 7.3.2.2.5. By Model Organisms
    - 7.3.2.2.6. By End User
- 7.3.3. United Kingdom Transgenic Animal Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By PCR
    - 7.3.3.2.3. By Technique
    - 7.3.3.2.4. By Application
    - 7.3.3.2.5. By Model Organisms
    - 7.3.3.2.6. By End User
- 7.3.4. Italy Transgenic Animal Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By PCR
    - 7.3.4.2.3. By Technique
    - 7.3.4.2.4. By Application
    - 7.3.4.2.5. By Model Organisms
    - 7.3.4.2.6. By End User
- 7.3.5. Spain Transgenic Animal Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By PCR
    - 7.3.5.2.3. By Technique
    - 7.3.5.2.4. By Application
    - 7.3.5.2.5. By Model Organisms
    - 7.3.5.2.6. By End User

8. Asia Pacific Transgenic Animal Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By PCR
- 8.2.3. By Technique
- 8.2.4. By Application
- 8.2.5. By Model Organisms
- 8.2.6. By End User
- 8.2.7. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Transgenic Animal Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By PCR
    - 8.3.1.2.3. By Technique
    - 8.3.1.2.4. By Application
    - 8.3.1.2.5. By Model Organisms
    - 8.3.1.2.6. By End User
- 8.3.2. India Transgenic Animal Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By PCR
    - 8.3.2.2.3. By Technique
    - 8.3.2.2.4. By Application
    - 8.3.2.2.5. By Model Organisms
    - 8.3.2.2.6. By End User
- 8.3.3. Japan Transgenic Animal Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By PCR
    - 8.3.3.2.3. By Technique
    - 8.3.3.2.4. By Application
    - 8.3.3.2.5. By Model Organisms
    - 8.3.3.2.6. By End User
- 8.3.4. South Korea Transgenic Animal Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By PCR
    - 8.3.4.2.3. By Technique
    - 8.3.4.2.4. By Application
    - 8.3.4.2.5. By Model Organisms
    - 8.3.4.2.6. By End User
- 8.3.5. Australia Transgenic Animal Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By PCR
    - 8.3.5.2.3. By Technique
    - 8.3.5.2.4. By Application
    - 8.3.5.2.5. By Model Organisms
    - 8.3.5.2.6. By End User

9. Middle East & Africa Transgenic Animal Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By PCR
- 9.2.3. By Technique
- 9.2.4. By Application
- 9.2.5. By Model Organisms
- 9.2.6. By End User
- 9.2.7. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Transgenic Animal Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By PCR
    - 9.3.1.2.3. By Technique
    - 9.3.1.2.4. By Application
    - 9.3.1.2.5. By Model Organisms
    - 9.3.1.2.6. By End User
- 9.3.2. UAE Transgenic Animal Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By PCR
    - 9.3.2.2.3. By Technique
    - 9.3.2.2.4. By Application
    - 9.3.2.2.5. By Model Organisms
    - 9.3.2.2.6. By End User
- 9.3.3. South Africa Transgenic Animal Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By PCR
    - 9.3.3.2.3. By Technique
    - 9.3.3.2.4. By Application
    - 9.3.3.2.5. By Model Organisms
    - 9.3.3.2.6. By End User

10. South America Transgenic Animal Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By PCR
- 10.2.3. By Technique
- 10.2.4. By Application
- 10.2.5. By Model Organisms
- 10.2.6. By End User
- 10.2.7. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Transgenic Animal Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By PCR
    - 10.3.1.2.3. By Technique
    - 10.3.1.2.4. By Application
    - 10.3.1.2.5. By Model Organisms
    - 10.3.1.2.6. By End User
- 10.3.2. Colombia Transgenic Animal Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By PCR
    - 10.3.2.2.3. By Technique
    - 10.3.2.2.4. By Application
    - 10.3.2.2.5. By Model Organisms
    - 10.3.2.2.6. By End User
- 10.3.3. Argentina Transgenic Animal Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By PCR
    - 10.3.3.2.3. By Technique
    - 10.3.3.2.4. By Application
    - 10.3.3.2.5. By Model Organisms
    - 10.3.3.2.6. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Transgenic Animal Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. C.H. Boehringer Sohn Ko. KG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. ELIAS Animal Health, LLC
15.3. Zoetis Inc.
15.4. AB Science S.A.
15.5. Karyopharm Therapeutics, Inc.
15.6. Vivesto AB
15.7. Merial Inc.
15.8. Elanco Animal Health, Inc.
15.9. Dechra Pharmaceuticals PLC
15.10. Torigen Pharmaceuticals Inc